The Anglo-Swedish pharmaceutical company reported total revenue of $15.2bn, up 11 per cent year on year at constant exchange ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...

British pharmaceutical giant AstraZeneca on Thursday said its net profit jumped 77 percent in the third quarter as the group expands its operations in the United States.

Core earnings rose 12% to $2.38 per share for the three months ended September 30, topping expectations of $2.29 per share. Revenue grew 10% at constant exchange rates to $15.19 billion, also ahead of ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London's most valuable listed company to retain its ...

(Reuters) -AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on ...

The latest investment brings the British pharma’s total investment at the site in Qingdao to $886 million. AstraZeneca ...

AstraZeneca has seen its fair value per share revised upward from $140.96 to $144.38. This change reflects growing analyst ...

AstraZeneca PLC ADR closed 6.26% below its 52-week high of $86.57, which the company achieved on October 6th.

"ESMO 2025: AstraZeneca and Daiichi Sankyo establish Enhertu in early breast cancer" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

CNW/ - AstraZeneca Canada (AstraZeneca) and the Leukemia & Lymphoma Society of Canada (LLSC) are proud to announce the ...

AstraZeneca shareholders approved a direct listing of the drugmaker's shares on the New York Stock Exchange on Monday, giving ...